(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 4.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.61%.
United Therapeutics's revenue in 2025 is $3,077,800,000.On average, 6 Wall Street analysts forecast UTHR's revenue for 2025 to be $144,885,089,119, with the lowest UTHR revenue forecast at $143,080,380,360, and the highest UTHR revenue forecast at $146,457,561,022. On average, 6 Wall Street analysts forecast UTHR's revenue for 2026 to be $151,162,629,963, with the lowest UTHR revenue forecast at $140,448,211,912, and the highest UTHR revenue forecast at $159,635,136,981.
In 2027, UTHR is forecast to generate $161,745,620,498 in revenue, with the lowest revenue forecast at $144,899,064,034 and the highest revenue forecast at $197,164,341,452.